WHO prequalifies first-ever malaria treatment for newborns and infants, adds new diagnostic tests
Published on April 24, 2026.
The World Health Organization (WHO) has prequalified the first treatment developed specifically for newborns and young infants, artemether-lumefantrine, to expand access to quality-assured treatment for one of the most underserved patient groups. The prequalification designation indicates that the medicine meets international standards of quality, safety, and efficacy. This will enable public sector procurement, helping to close a treatment gap for some 30 million babies born each year in malaria-endemic areas of Africa. On 14 April 2026, WHO also prequalified three new rapid diagnostic tests (RDTs) designed to address emerging diagnostic challenges for malaria. The new tests target a different parasite protein (pf-LDH) that the malaria parasite cannot easily shed.
Related Articles
Simple act can lower your risk of early death by 45% — you’ve probably already done it
A study reveals that voting in political elections can lower early death risk among older adults by 45%, with long-term benefits like longevity and community engagement.
Kansas clinic has ‘serious concerns’ after Dillons blocks some prescriptions
Hutchinson Clinic has expressed serious concerns after Dillons stopped filling controlled substance prescriptions from three providers, potentially impacting patient care and safety.
Healthcare Giant Allegedly Lost, Mishandled, And Desecrated Corpses Of Deceased Patients
CommonSpirit Health faces allegations of negligence and neglect for the deaths of patients, including neglect that led to improper burial practices and multiple lawsuits.